Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.
Read Full NewsThe U.S. Food and Drug Administration on Thursday authorized the emergency use of a generic over-the-counter tablet to treat infestations caused by the New World screwworm...
Extent of lymph node dissection, defining high-risk criteria, oral androgen deprivation therapy (ADT), and darolutamide plus ADT are among the highlights for prostate cancer management from AUA 2026.
A novel PET imaging agent identified AD-related tau earlier and in more patients than the currently used tracer, possibly speeding AD detection, a new study shows.
A Kaiser Permanente study shows some people who initially struggle with CPAP adherence still use the device at 1 year, suggesting CMS’ 90-day cutoff is too strict.
Even though the real-world patients in a phase 4 study were older and heavier, ublituximab provided safety and tolerability at least comparable to that in 2 pivotal trials.
Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a...
Three laboratories in Democratic Republic of Congo have run out of supplies to test for Ebola, the World Health Organization said, as the outbreak of the dangerous...
1.
A specific drug combination is being tested in a clinical trial for the deadly brain cancer glioblastoma.
2.
Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.
3.
'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma
4.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
5.
Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer
1.
Cancer Cachexia: Emerging Therapeutic Strategies
2.
Modern Concepts in Oncology Across Clinical Settings
3.
Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives
4.
The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge